Iterum Therapeutics to Present Data at IDWeek 2021
September 28 2021 - 7:30AM
Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a
clinical-stage pharmaceutical company focused on developing next
generation oral and IV antibiotics to treat infections caused by
multi-drug resistant pathogens in both community and hospital
settings, today announced a data presentation at the Infectious
Disease Society of America (IDSA) IDWeekTM 2021, taking place
virtually from September 29 – October 3, 2021.
Title: In Vitro Antibacterial
Susceptibility Testing of Sulopenem Against Category A and B
Bio-threat Bacterial PathogensPresenting Author:
Steven I. AroninDate: September 29,
2021Poster Session: A1. Novel AgentsPoster
Number: 1072
About Iterum Therapeutics
plc
Iterum Therapeutics plc is a clinical-stage
pharmaceutical company dedicated to developing differentiated
anti-infectives aimed at combatting the global crisis of multi-drug
resistant pathogens to significantly improve the lives of people
affected by serious and life-threatening diseases around the world.
Iterum Therapeutics is advancing its first compound, sulopenem, a
novel penem anti-infective compound, in Phase 3 clinical
development with an oral formulation and IV formulation. Sulopenem
has demonstrated potent in vitro activity against a wide variety of
gram-negative, gram-positive and anaerobic bacteria resistant to
other antibiotics. Iterum Therapeutics has received Qualified
Infectious Disease Product (QIDP) and Fast Track designations for
its oral and IV formulations of sulopenem in seven indications.
Forward-Looking Statements
This press release contains forward-looking
statements. In some cases, forward-looking statements can be
identified by words such as “may,” “believes,” “intends,” “seeks,”
“anticipates,” “plans,” “estimates,” “expects,” “should,”
“assumes,” “continues,” “could,” “would,” “will,” “future,”
“potential” or the negative of these or similar terms and phrases.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the Company’s actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Forward-looking
statements include all matters that are not historical facts.
Actual future results may be materially different from what is
expected due to factors largely outside the Company’s control,
including uncertainties inherent in the initiation and conduct of
clinical and nonclinical development, including any additional
trials that may be conducted in response to the CRL, availability
and timing of data from such clinical and nonclinical development,
changes in regulatory requirements or decisions of regulatory
authorities, the timing or likelihood of regulatory filings and
approvals, including any potential resubmission of the NDA, changes
in public policy or legislation, commercialization plans and
timelines, if oral sulopenem is approved, the actions of
third-party clinical research organizations, suppliers and
manufacturers, the accuracy of the Company’s expectations regarding
how far into the future the Company’s cash on hand will fund the
Company’s ongoing operations, the impact of COVID-19 and related
responsive measures thereto, risks and uncertainties concerning the
outcome, impact, effects and results of the Company’s evaluation of
corporate, strategic, financial and financing alternatives,
including the terms, timing, structure, value, benefits and costs
of any corporate, strategic, financial or financing alternative and
the Company’s ability to complete one at all and other factors
discussed under the caption “Risk Factors” in its Quarterly Report
on Form 10- Q filed with the Securities and Exchange Commission
(the “SEC”) on August 13, 2021, and other documents filed with the
SEC from time to time. Forward-looking statements represent the
Company’s beliefs and assumptions only as of the date of this press
release. Except as required by law, the Company assumes no
obligation to update these forward-looking statements publicly, or
to update the reasons actual results could differ materially from
those anticipated in the forward-looking statements, even if new
information becomes available in the future.
Investor Contact:Judy Matthews Chief
Financial Officer312-778-6073IR@iterumtx.com
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Sep 2023 to Sep 2024